Prostatype Genomics AB Stock: price and insider trades · Sweden

Prostatype Genomics AB belongs to the Health Care sector. Filings by its managers are published through Finansinspektionen. In the past year (18 October 2025 to 18 October 2026), 15 filings came from 8 insiders.

Purchases and sales both appear in the filings: 8 purchases (5 insiders, €283k) and 1 sale (1 insider, €152). No amount is published for 2 filings, which the totals therefore leave out. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. At €200k, the purchase published on 6 August 2026 by Håkan Englund is the largest of the period (12.6% of market cap). On the buying side, the filings list 4 board members and 1 chief executive among the declarants.

Compared with its exchange (890 companies, median 7 filings), a count of 15 filings is above the norm. Over the whole record (from 2025), the tally stands at 10 purchases and 1 sale.

In the case of 5 purchases, another manager of the company was buying within the same 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The most recent open-market purchase was published on 18 September 2026, 29 days ago. The median gap between a trade and its publication by Finansinspektionen is 1 day. The regulation allows three business days to notify a trade (MAR article 19).

Elsewhere in the same sector, our signals recently picked up insider purchases at Anixa Biosciences Inc and Vivos Inc. These figures are compiled from regulatory filings published by Finansinspektionen. They describe what insiders did and are not a recommendation.